Predict your next investment

MerLion Pharmaceuticals company logo
Corporation
HEALTHCARE | Drug Discovery
merlionpharma.com

See what CB Insights has to offer

Founded Year

2002

Stage

Private Equity - II | Alive

Total Raised

$50.5M

About MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.

MerLion Pharmaceuticals Headquarter Location

Robert-Rossle-Strasse 10

Berlin, 13125,

Germany

Latest MerLion Pharmaceuticals News

Press Release : MerLion Pharmaceuticals Completes Growth Financing Round

May 18, 2021

05/18/2021 | 03:31am EDT Message : *Required fields - Proceeds will be used to facilitate MerLion`s production and marketlaunch of Xtoro(TM) Berlin, (18/05/2021) - MerLion Pharmaceuticals GmbH (MerLion), abiopharmaceutical company focused on research and development of novelantibiotics for the treatment of serious bacterial infections, todayannounced the successful completion of a growth financing round raisedvia a private placement to European strategic investors. The funds raised will primarily be used to finance the production andmarket launch of MerLion's US FDA and Health Canada approved drugXtoro(TM) , an otic suspension containing finafloxacin for treatment ofear infections. In addition to existing investors such as HeidelbergCapital and VlPartners, new strategic investors such as Denk Pharma GmbH & Co. KG havetaken part in the round. Further details were not disclosed. "This is a significant milestone in our mission to successfully launchXtoro, an otic formulation of our antibiotic finafloxacin, in the US andCanada," said Dr. Andreas Vente, Managing Director of MerLion. "Thisfinancing is proof of the high potential of our lead drug and theconfidence of our investors in our strategy." "We invest in projects and technologies that contribute significantly topatients' healing," said Stephan Huber, Managing Director at DenkPharma. "Xtoro is an FDA-approved product for the treatment of AcuteOtitis Externa in children and adults. Its superior, fast actingproperties will aid patients considerably in their recovery." ### About MerLion Pharmaceuticals MerLion Pharmaceuticals GmbH is a is a privately held companybiopharmaceutical company headquartered in Berlin, Germany. The companyfocuses on the advanced clinical development of its antibacterial leadprogram, finafloxacin. MerLion is supported by a group of leading globalinvestors. For more information, please visit https://www.globenewswire.com/Tracker?data=PmjBOnLu2EpCTFsUWozejL5dzzvifUf7Sl1KEmzw04tCCPFKx47FOSgdhm_fFZeqby50V8Taed2AlJ-UUPcHqZCUOJffXB1i6z_kljGycwU= http://www.merlionpharma.com POELLATH, Munich, Dr. Michael Inhester and Adalbert Makos advisedMerLion on the investment and capital raise. About Finafloxacin Finafloxacin is a novel fluoroquinolone antibiotic with best-in-classfeatures. Finafloxacin combines well-known, significant efficacy andresistance-breaking capabilities with an outstanding safety profile. Inclinical and pre-clinical settings, the compound has shown asubstantially improved therapeutic profile as compared to the existinggold standard and a broad utility in treating many severe infections,including those caused by resistant Gram-negative pathogens.Finafloxacin is available as intravenous, oral, and topical formulation. Finafloxacin's superior profile arises from the compound's unique modeof action, being equally active at physiological pH conditions and inthe acidic environments which occur at most bacterial infection sites.Most other antibiotics, including other fluoroquinolones, show decreasedactivity under acidic tissue conditions, which results in a significantreduction of their overall efficacy. In addition to the FDA-approved liquid suspension formulation ofXTORO(TM), MerLion has also developed intravenous and oral formulationsof finafloxacin with equivalent bioavailability, which may offerphysicians various options for in-hospital and out-patient treatmentregimens. The impact of finafloxacin for the treatment of infections caused by thebiological intracellular threat agents Burkholderia pseudomallei,Francisella tularensis, Yersinia pestis and other multi-drug resistant(MDR) pathogens of clinical significance are currently beinginvestigated in a joint project with the Defense Science and TechnologyLaboratory, UK (Dstl). Contact: Dr. Andreas Vente Managing Director MerLion Pharmaceuticals Gmbh Robert-Roessle-Str. 10 13125 Berlin, Germany Phone: +49 (0) 30 9489-4050 Fax: +49 (0) 30 9489-4051 https://www.globenewswire.com/Tracker?data=CVipQ0sIzJBVJKWBQpgNzb7u4ViZHY8_B_Qu7duzRj8h6D6zXrUqPGBmsHJdcUe0pm5t0bVQWZdaQejqRdsId3H8ECs9xjOyavdQ3YUinyLFnCoUSw6mvHnD_KZBZmIV enquiry@merlionpharma.de (END) Dow Jones Newswires

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MerLion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MerLion Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

818 items

MerLion Pharmaceuticals Patents

MerLion Pharmaceuticals has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/9/2015

3/3/2020

Amines, Piperidines, Sodium compounds, Phenols, Ketones

Grant

Application Date

10/9/2015

Grant Date

3/3/2020

Title

Related Topics

Amines, Piperidines, Sodium compounds, Phenols, Ketones

Status

Grant

MerLion Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MerLion Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.